Hence, we evaluated baseline WT1 expression in KS tumors in a large group of individuals with advanced HIV-associated KS who participated in a prospectively randomized therapeutic trial [54], plus additional cohorts of both non-HIV and HIV-associated KS. This evidence concerns the gene WT1 and Kaposi's sarcoma.